GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

GSK2315698

Company
GlaxoSmithKline
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01323985

    SAP Depleter Dose Escalation Study in Healthy Volunteers

    Not yet reported GlaxoSmithKline 21 participants Est. completion 2011-06-30 1 site Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Completed NCT NCT01406314

    SAP Depleter Dose Assessment Study in Patients

    Not yet reported GlaxoSmithKline 17 participants Est. completion 2012-11-14 1 site Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Completed NCT NCT01777243

    A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis

    Not yet reported GlaxoSmithKline 25 participants Est. completion 2015-12-22 2 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Terminated NCT NCT02603172

    A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis

    Not yet reported GlaxoSmithKline 23 participants Est. completion 2017-05-10 1 site
    Other conditions: Amyloidosis
    View official trial listing →
  • Completed NCT NCT02953808

    Phase 1 Study of GSK2315698 in Healthy Japanese Subjects

    Not yet reported GlaxoSmithKline 18 participants Est. completion 2016-12 1 site Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Terminated NCT NCT03044353

    Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

    Not yet reported GlaxoSmithKline 7 participants Est. completion 2019-01-03 3 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Terminated NCT NCT03417830

    Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

    Not yet reported GlaxoSmithKline 2 participants Est. completion 2018-07-20 1 site Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: GSK2315698, GSK2315698 (CPHPC)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.